摘要
目的研究卡格列净联合吡格列酮治疗2型糖尿病的临床疗效。方法选取2021年12月—2022年12月广元市中心医院全科医学科收治的80例糖尿病患者为研究对象,按计算机表法分为对照组和研究组,每组40例。对照组给予盐酸吡格列酮片治疗,研究组在对照组基础上同时服用卡格列净片。两组连续用药5周后,将两组患者治疗前后临床疗效、症状存在时间、血糖水平、血清因子变化及不良反应发生情况做比较。结果研究组临床治疗总有效率(97.50%)明显高于对照组(80.00%),差异有统计学意义(P<0.05);研究组患者多饮、消瘦、多尿、乏力等症状存在时间均短于对照组,差异有统计学意义(P<0.05);治疗前,两组患者FPG、2 hPG、HbA1c水平对比差异无统计学意义(P>0.05),治疗后,两组患者FPG、2 hPG、HbA1c水平明显下降,且研究组低于对照组,差异有统计学意义(P<0.05);治疗前,两组患者IL-6、TNF-α、CRP水平对比差异无统计学意义(P>0.05),治疗后,研究组IL-6、TNF-α、CRP水平低于对照组,差异有统计学意义(P<0.05);研究组患者不良反应发生率(5.00%)明显低于对照组(25.00%),差异有统计学意义(P<0.05)。结论卡格列净联合吡格列酮治疗2型糖尿病,可使患者血糖明显降低,血清因子水平得到改善,且用药安全性较高,有很好的治疗效果。
Objective To study the clinical efficacy of the treatment of type 2 diabetes mellitus with canagliflozin combined with pioglitazone.Methods A total of 80 patients with diabetes mellitus admitted to the Department of General Practice of Guangyuan Central Hospital from December 2021 to December 2022 were selected as the research objects,and they were divided into control group and study group according to the computer table method,with 40 cases in each group.The control group was treated with pioglitazone hydrochloride tablets,and the study group was treated with cardagliflozin tablets on the basis of the control group.After 5 weeks of continuous medication,the clinical efficacy,symptom existence time,blood glucose level,serum factor changes and adverse reactions of the two groups were compared before and after treatment.Results The total effective rate of clinical treatment in the study group(97.50%)was significantly higher than that in the control group(80.00%),the difference was statistically significant(P<0.05).The time of symptoms such as polydipsia,emaciation,polyuria and fatigue in the study group was shorter than that in the control group,and the difference was statistically significant(P<0.05).Before treatment,there was no significant difference in the levels of FPG,2 hPG and HbA1c between the two groups(P>0.05).After treatment,the levels of FPG,2 hPG and HbA1c in the two groups decreased significantly,and those in the study group were lower than the control group,the differences were statistically significant(P<0.05).Before treatment,there was no significant difference in the levels of IL-6,TNF-αand CRP between the two groups(P>0.05).After treatment,the levels of IL-6,TNF-αand CRP in the study group were lower than those in the control group,and the difference was statistically sig nificant(P<0.05).The incidence of adverse reactions in the study group(5.00%)was significantly lower than that in the control group(25.00%),and the difference was statistically significant(P<0.05).Conclusion The treatment of type 2 diabetes mellitus with the combination of pioglitazone can significantly reduce the blood glucose and improve the serum factor level of patients,and the safety of drug use is high,which has good therapeutic effect.
作者
黄源
HUANG Yuan(Department of General Medicine,Guangyuan Central Hospital,Guangyuan,Sichuan Province,628000 China)
出处
《糖尿病新世界》
2023年第11期107-110,共4页
Diabetes New World Magazine
关键词
卡格列净
吡格列酮
2型糖尿病
血糖
糖化血红蛋白
肿瘤坏死因子-Α
Canagliflozin
Pioglitazone
Type 2 diabetes mellitus
Blood glucose
Glycated hemoglobin
Tumor necrosis factor-α
